Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 750 of 1048 entries
View as:

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06331169 Org: User:
Start: 07/31/24 End: 06/30/27 Due: 06/30/28

Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From Cerebral Hemorrhage

Phase: N/A Priority: Normal
NCT ID: NCT00815737 Org: User:
Start: 01/31/09 End: - Due: -

Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy

Phase: N/A Priority: Normal
NCT ID: NCT01402180 Org: User:
Start: 12/31/10 End: 12/31/15 Due: 12/31/16

500mg Fulvestrant Versus Exemestane in MBC

Phase: N/A Priority: Normal
NCT ID: NCT03575260 Org: User:
Start: 07/01/17 End: 01/15/19 Due: 01/15/20

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06447636 Org: User:
Start: 08/01/24 End: 08/31/28 Due: 08/31/29

Social Media-based Vaccine Confidence and Hesitancy Monitoring

Phase: N/A Priority: Normal
NCT ID: NCT05442762 Org: User:
Start: 03/01/22 End: 06/24/22 Due: 06/24/23

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Phase: N/A Priority: Normal
NCT ID: NCT05254847 Org: User:
Start: 12/30/21 End: 12/31/24 Due: 12/31/25

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06370754 Org: User:
Start: 04/30/24 End: 04/30/27 Due: 04/30/28

New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases

Phase: N/A Priority: Normal
NCT ID: NCT01307878 Org: User:
Start: 06/30/12 End: 06/30/21 Due: 06/30/22

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Phase: N/A Priority: Normal
NCT ID: NCT04764214 Org: User:
Start: 03/01/21 End: 07/20/23 Due: 07/20/24

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06218810 Org: User:
Start: 01/01/24 End: 12/31/26 Due: 12/31/27

Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT05462470 Org: User:
Start: 01/01/08 End: 04/30/22 Due: 04/30/23

A Cohort Study of Musculoskeletal Health in Patients With Breast Cancer During Aromatase Inhibitors Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05921617 Org: User:
Start: 04/27/23 End: 04/27/25 Due: 04/27/26

Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT06501378 Org: User:
Start: 07/01/24 End: 07/31/25 Due: 07/31/26

Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT06501391 Org: User:
Start: 07/01/24 End: 07/31/27 Due: 07/31/28

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Phase: N/A Priority: Normal
NCT ID: NCT06578286 Org: User:
Start: 09/30/24 End: 09/30/30 Due: 09/30/31

Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial

Phase: N/A Priority: Normal
NCT ID: NCT01528826 Org: User:
Start: 12/31/11 End: 07/31/13 Due: 07/31/14

Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03799692 Org: User:
Start: 11/19/18 End: 07/30/19 Due: 07/30/20

Reverse HER2-negative Immune Resistant Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06731140 Org: User:
Start: 02/12/25 End: 10/31/27 Due: 10/31/28

Patient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage

Phase: N/A Priority: Normal
NCT ID: NCT06965556 Org: User:
Start: 06/01/25 End: 10/31/26 Due: 10/31/27

Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents

Phase: N/A Priority: Normal
NCT ID: NCT04472143 Org: User:
Start: 07/18/20 End: 12/31/22 Due: 12/31/23

Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01604798 Org: User:
Start: 01/31/07 End: 05/31/12 Due: 05/31/13

Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment

Phase: N/A Priority: Normal
NCT ID: NCT05717582 Org: User:
Start: 05/01/23 End: 12/31/26 Due: 12/31/27

Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction

Phase: N/A Priority: Normal
NCT ID: NCT05512286 Org: User:
Start: 08/25/22 End: 10/01/27 Due: 10/01/28

Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT05354674 Org: User:
Start: 09/01/23 End: 07/01/28 Due: 07/01/29